Carisma Therapeutics(CARM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CARM Carisma Therapeutics

Market Closed 11-22 16:00:00 EST

0.8225

-0.0253

-2.98%

盘后0.8600

+0.0375+4.56%

19:14 EST

High0.8593	Low0.8200	Vol206.32K
Open0.8478	D1 Closing0.8478	Amplitude4.64%
Mkt Cap34.34M	Tradable Cap18.61M	Total Shares41.75M
T/O173.56K	T/O Rate0.91%	Tradable Shares22.62M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"CARM","market":"US","secType":"STK","nameCN":"Carisma Therapeutics","latestPrice":0.8225,"timestamp":1732309200000,"preClose":0.8478,"halted":0,"volume":206319,"hourTrading":{"tag":"盘后","latestPrice":0.86,"preClose":0.8225,"latestTime":"19:14 EST","volume":285,"amount":241.9454,"timestamp":1732320867013},"delay":0,"floatShares":22623853,"shares":41750109,"eps":-1.550993,"marketStatus":"Market Closed","change":-0.0253,"latestTime":"11-22 16:00:00 EST","open":0.8478,"high":0.8593,"low":0.82,"amount":173564.68273169998,"amplitude":0.046355,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.550993,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1732525200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.8478,"preHourTrading":{"tag":"盘前","latestPrice":0.8798,"preClose":0.8478,"latestTime":"09:05 EST","volume":129,"amount":112.63290570000001,"timestamp":1732284326008},"postHourTrading":{"tag":"盘后","latestPrice":0.86,"preClose":0.8225,"latestTime":"19:14 EST","volume":285,"amount":241.9454,"timestamp":1732320867013},"volumeRatio":1.4402179621797102},"requestUrl":"/m/hq/s/CARM/tweets","defaultTab":"tweets","newsList":[{"id":"2484982876","title":"Carisma Therapeutics Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2484982876","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484982876?lang=en_us&edition=fundamental","pubTime":"2024-11-19 05:54","pubTimestamp":1731966840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CARM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 18, 2024 16:54 ET (21:54 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CARM"],"gpt_icon":0},{"id":"2484734643","title":"Carisma Therapeutics Says Preclinical Data Support Potential of Engineered Macrophages to Treat Liver Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2484734643","media":"MT Newswires Live","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484734643?lang=en_us&edition=fundamental","pubTime":"2024-11-18 17:04","pubTimestamp":1731920652,"startTime":"0","endTime":"0","summary":"Carisma Therapeutics  said Sunday that new preclinical data showed the potential of the company's engineered macrophages in multiple liver fibrosis models.Results of the study showed that the engineered macrophages significantly reduced liver fibrosis and hepatic stellate cell activation. The engineered macrophages were also well tolerated in the study, the company said.The company anticipates to nominate a development candidate for its liver fibrosis program in Q1 2025.Price: 1.0407, Change: -0.01, Percent Change: -0.89","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CARM","BK4139"],"gpt_icon":0},{"id":"2484687062","title":"Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2484687062","media":"PR Newswire","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484687062?lang=en_us&edition=fundamental","pubTime":"2024-11-17 20:30","pubTimestamp":1731846600,"startTime":"0","endTime":"0","summary":"New preclinical results support the anti-fibrotic potential of engineered macrophages in multiple fibrosis models. PHILADELPHIA, Nov. 17, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today presented promising preclinical data on engineered macrophages for treating liver fibrosis at the American Association for the Study of Liver Diseases  The Liver Meeting 2024. These results underscore the pre-clinical efficacy of Carisma's engineered macrophages in multiple liver fibrosis models and offer a novel, off-the-shelf potential treatment option for patients with fibrotic liver disease including advanced metabolic dysfunction-associated steatohepatitis .\"We are pleased to present compelling preclinical data supporting the therapeutic potential of our engineered macrophages to address a critical unmet need in liver fibrosis, which is found in advanced stages of MASH,\" said Michael ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/aGF3Q8ckRSfUVydORVClCw--~B/aD0xMDQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/ffc8d7a6f9a8e6fb35c642709403ae67","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/aGF3Q8ckRSfUVydORVClCw--~B/aD0xMDQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/ffc8d7a6f9a8e6fb35c642709403ae67"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/carisma-therapeutics-presents-promising-preclinical-123000147.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/carisma-therapeutics-presents-promising-preclinical-123000147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CARM","BK4139"],"gpt_icon":0},{"id":"2482644137","title":"Carisma Therapeutics Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2482644137","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482644137?lang=en_us&edition=fundamental","pubTime":"2024-11-12 06:20","pubTimestamp":1731363600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CARM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 11, 2024 17:20 ET (22:20 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CARM"],"gpt_icon":0},{"id":"2482221461","title":"Optimistic Buy Rating for Carisma Therapeutics Amid Promising CAR-Myeloid Developments and Strong Financial Standing","url":"https://stock-news.laohu8.com/highlight/detail?id=2482221461","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482221461?lang=en_us&edition=fundamental","pubTime":"2024-11-11 14:15","pubTimestamp":1731305716,"startTime":"0","endTime":"0","summary":"Jack Allen, an analyst from Robert W. Baird, maintained the Buy rating on Carisma Therapeutics (CARM – Research Report). The associated price targe...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/optimistic-buy-rating-for-carisma-therapeutics-amid-promising-car-myeloid-developments-and-strong-financial-standing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/optimistic-buy-rating-for-carisma-therapeutics-amid-promising-car-myeloid-developments-and-strong-financial-standing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CARM","CAR"],"gpt_icon":0},{"id":"2482297232","title":"Carisma Therapeutics Third Quarter 2024 Earnings: Misses Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2482297232","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482297232?lang=en_us&edition=fundamental","pubTime":"2024-11-10 22:28","pubTimestamp":1731248883,"startTime":"0","endTime":"0","summary":"Carisma Therapeutics ( NASDAQ:CARM ) Third Quarter 2024 Results Key Financial Results Revenue: US$3.39m (down 12% from...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-carm/carisma-therapeutics/news/carisma-therapeutics-third-quarter-2024-earnings-misses-expe","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CARM"],"gpt_icon":0},{"id":"2481174631","title":"BRIEF-Carisma Unveils Pre-Clinical Data On Anti-GPC3 In Vivo CAR-M Therapy For Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2481174631","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481174631?lang=en_us&edition=fundamental","pubTime":"2024-11-08 20:39","pubTimestamp":1731069540,"startTime":"0","endTime":"0","summary":"Nov 8  - Carisma Therapeutics Inc   :   * CARISMA UNVEILS PROMISING PRE-CLINICAL DATA ON ANTI-GPC3 IN VIVO CAR-M THERAPY FOR HEPATOCELLULAR CARCINOMA   * CARISMA -ANTI-GPC3 IN VIVO CAR-M THERAPY WELL TOLERATED IN MOUSE MODELS, HIGHLIGHTING ITS POTENTIAL AS AN OFF--SHELF TREATMENT FOR GPC3+ SOLID TUMORSSource text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4588","BK4022","CAR","BK4534","BK4501","BK4551","CARM","MRNA","BK4533","BK4139","BK4230","BK4548","BK4568","BK4585"],"gpt_icon":0},{"id":"2481171150","title":"Carisma Unveils Promising Pre-Clinical Data on Anti-Gpc3 in Vivo Car-M Therapy for Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2481171150","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481171150?lang=en_us&edition=fundamental","pubTime":"2024-11-08 20:30","pubTimestamp":1731069008,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nFWN3MF1SM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4551","MRNA","BK4534","BK4533","BK4548","BK4568","CARM","BK4139","BK4588","BK4501","BK4532","BK4585"],"gpt_icon":0},{"id":"2481171130","title":"Carisma -Anti-Gpc3 in Vivo Car-M Therapy Well Tolerated in Mouse Models, Highlighting Its Potential as an off--Shelf Treatment for Gpc3+ Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2481171130","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481171130?lang=en_us&edition=fundamental","pubTime":"2024-11-08 20:30","pubTimestamp":1731069008,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nFWN3MF1SM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4501","BK4568","BK4585","BK4548","BK4551","BK4588","BK4534","BK4533","CARM","BK4532","MRNA"],"gpt_icon":0},{"id":"2481293174","title":"Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2481293174","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481293174?lang=en_us&edition=fundamental","pubTime":"2024-11-08 20:30","pubTimestamp":1731069000,"startTime":"0","endTime":"0","summary":"New findings showcase the potential of in vivo CAR-M technology as an effective, off-the-shelf treatment for hepatocellular carcinoma . PHILADELPHIA, Nov. 8, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced positive pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte  therapy for hepatocellular carcinoma , developed in collaboration with Moderna, Inc. . The data demonstrated that the development candidate can successfully create CAR-M directly in vivo, reprogramming endogenous myeloid cells to target and destroy Glypican-3 , expressing cancer cells.\"These preclinical data highlights the successful application of our mRNA/LNP platform in enabling in vivo cell therapy,\" saidLin Guey, PhD, CSO ofTherapeutic Research Ventures, Moderna.\"We look forward to further advancing the anti-GPC3 in vivo CAR-M therapy for HCC patients an","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/aGF3Q8ckRSfUVydORVClCw--~B/aD0xMDQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/ffc8d7a6f9a8e6fb35c642709403ae67","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/aGF3Q8ckRSfUVydORVClCw--~B/aD0xMDQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/ffc8d7a6f9a8e6fb35c642709403ae67"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/carisma-unveils-promising-pre-clinical-123000531.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/carisma-unveils-promising-pre-clinical-123000531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4006","BK4022","MRNA","HCC","BK4139","BK4230","CAR","CARM"],"gpt_icon":0},{"id":"2481184690","title":"Carisma Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2481184690","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481184690?lang=en_us&edition=fundamental","pubTime":"2024-11-07 23:10","pubTimestamp":1730992216,"startTime":"0","endTime":"0","summary":"* Carisma Therapeutics Inc    reported a quarterly adjusted loss of 31 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -53 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Carisma Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CARM"],"gpt_icon":0},{"id":"2481907079","title":"Carisma Therapeutics Is Maintained at Buy by EF Hutton","url":"https://stock-news.laohu8.com/highlight/detail?id=2481907079","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481907079?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:43","pubTimestamp":1730986980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CARM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 07, 2024 08:43 ET (13:43 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CARM"],"gpt_icon":0},{"id":"2481909085","title":"CARISMA Therapeutics' Q3 Cash And Cash Equivalents Of $26.9M Expected To Fund The Company Into The Third Quarter Of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2481909085","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481909085?lang=en_us&edition=fundamental","pubTime":"2024-11-07 20:56","pubTimestamp":1730984167,"startTime":"0","endTime":"0","summary":"CARISMA Therapeutics' Q3 Cash And Cash Equivalents Of $26.9M Expected To Fund The Company Into The Third Quarter Of 2025","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/general/biotech/24/11/41804806/carisma-therapeutics-q3-cash-and-cash-equivalents-of-26-9m-expected-to-fund-the-company-into-the-","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CARM","BK4139","LENZ"],"gpt_icon":0},{"id":"2481808906","title":"Carisma Therapeutics Inc: Cash & Cash Equivalents of $26.9 Million Expected to Fund Co Into Q3 of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2481808906","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481808906?lang=en_us&edition=fundamental","pubTime":"2024-11-07 20:30","pubTimestamp":1730982609,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nTUABRZZ9K:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CARM","BK4139"],"gpt_icon":0},{"id":"2481050929","title":"Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2481050929","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481050929?lang=en_us&edition=fundamental","pubTime":"2024-11-07 20:30","pubTimestamp":1730982609,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nTUABRZZ9K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CARM","BK4139"],"gpt_icon":0},{"id":"2481906520","title":"Press Release: Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2481906520","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481906520?lang=en_us&edition=fundamental","pubTime":"2024-11-07 20:30","pubTimestamp":1730982600,"startTime":"0","endTime":"0","summary":"Initial results from the Phase 1 study of CT-0525, lead product candidate, expected in the first quarter of 2025. Nomination of a development candidate for liver fibrosis program expected in the first quarter of 2025. New preclinical efficacy data from the anti-GPC3 in vivo CAR-M therapy to be presented on November 8 at SITC 2024 Annual Meeting. \"Our recent progress across clinical and preclinical programs demonstrates our commitment to pioneering therapies that address significant unmet medical needs,\" said Steven Kelly, President and CEO of Carisma Therapeutics. \"We are advancing on multiple fronts. We expect to report initial data from the Phase 1 study of CT-0525 in the first quarter of 2025. We also recently nominated our first development candidate in hepatocellular carcinoma with Moderna and are excited to bring additional in vivo CAR-M therapies forward, including autoimmune targets. Our liver fibrosis program is progressing as well, with the nomination of a development candida","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","TIP","BK4006","SITC","BK4231","R","BK4139","BK4232","BK4080","BK4588","BK4230","BK4585","CAR","CARM","HCC"],"gpt_icon":0},{"id":"2481202607","title":"Carisma Therapeutics Inc  expected to post a loss of 26 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2481202607","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481202607?lang=en_us&edition=fundamental","pubTime":"2024-11-06 22:17","pubTimestamp":1730902645,"startTime":"0","endTime":"0","summary":"Carisma Therapeutics Inc  expected to post a loss of26cents a share - Earnings Preview Carisma Therapeutics Inc CARM.OQ CARM.O is expected to show a rise in quarterly revenue when it reports  results ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241106:nL8N3MD335:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CARM"],"gpt_icon":0},{"id":"2481071415","title":"Carisma to present new data on CAR-M therapy for hepatocellular carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2481071415","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481071415?lang=en_us&edition=fundamental","pubTime":"2024-11-05 22:15","pubTimestamp":1730816132,"startTime":"0","endTime":"0","summary":"Carisma Therapeutics (CARM) announced the upcoming presentation of new pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macroph...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/carisma-to-present-new-data-on-car-m-therapy-for-hepatocellular-carcinoma?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/carisma-to-present-new-data-on-car-m-therapy-for-hepatocellular-carcinoma?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4022","BK4230","CAR","BK4139","CARM"],"gpt_icon":0},{"id":"2481502299","title":"Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481502299","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481502299?lang=en_us&edition=fundamental","pubTime":"2024-11-05 22:05","pubTimestamp":1730815500,"startTime":"0","endTime":"0","summary":"Pre-clinical data demonstrate robust anti-tumor activity and a novel off-the-shelf approach for GPC3+ solid tumors. PHILADELPHIA, Nov. 5, 2024 /PRNewswire/ --Carisma Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the upcoming presentation of new pre-clinical data on its anti-GPC3in vivochimeric antigen receptor macrophage and monocyte therapy for the treatment of hepatocellular carcinoma , developed in collaboration with Moderna, Inc. . The data will be presented in a poster session at the Society for Immunotherapy of Cancer  Annual Meeting in Houston, Texas, on November 8, 2024.The abstract, titled \"Pre-Clinical Efficacy of a Novel Anti-GPC3 In Vivo CAR-M for Hepatocellular Carcinoma,\" presents the first pre-clinical data on the development candidate targeting Glypican-3 , a tumor-associated antigen commonly expressed in HCC. This novel off-the-shelf approach reprograms endogenous myeloid","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/aGF3Q8ckRSfUVydORVClCw--~B/aD0xMDQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/ffc8d7a6f9a8e6fb35c642709403ae67","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/aGF3Q8ckRSfUVydORVClCw--~B/aD0xMDQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/ffc8d7a6f9a8e6fb35c642709403ae67"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/carisma-therapeutics-present-data-anti-140500157.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/carisma-therapeutics-present-data-anti-140500157.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4022","CAR","BK4230","MRNA","CARM","BK4139"],"gpt_icon":0},{"id":"2479760324","title":"BRIEF-Carisma Therapeutics Announces Changes To Its Board Of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2479760324","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479760324?lang=en_us&edition=fundamental","pubTime":"2024-10-31 06:33","pubTimestamp":1730327587,"startTime":"0","endTime":"0","summary":"Oct 30 (Reuters) - Carisma Therapeutics Inc   :   * CARISMA THERAPEUTICS ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORSSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CARM","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sesenbio.com","stockEarnings":[{"period":"1week","weight":-0.0687},{"period":"1month","weight":-0.1856},{"period":"3month","weight":-0.2721},{"period":"6month","weight":-0.3907},{"period":"1year","weight":-0.6812},{"period":"ytd","weight":-0.7193}],"compareEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":0.0303},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1248},{"period":"1year","weight":0.3088},{"period":"ytd","weight":0.2529}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.118068},{"month":2,"riseRate":0.3,"avgChangeRate":0.03966},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.09024},{"month":4,"riseRate":0.545455,"avgChangeRate":0.307249},{"month":5,"riseRate":0.545455,"avgChangeRate":0.110205},{"month":6,"riseRate":0.727273,"avgChangeRate":0.139785},{"month":7,"riseRate":0.181818,"avgChangeRate":0.036568},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.01952},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.081936},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.064229},{"month":11,"riseRate":0.454545,"avgChangeRate":0.007962},{"month":12,"riseRate":0.5,"avgChangeRate":-0.004255}],"exchange":"NASDAQ","name":"Carisma Therapeutics","nameEN":"Carisma Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Carisma Therapeutics(CARM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Carisma Therapeutics(CARM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Carisma Therapeutics,CARM,Carisma Therapeutics股票,Carisma Therapeutics股票老虎,Carisma Therapeutics股票老虎国际,Carisma Therapeutics行情,Carisma Therapeutics股票行情,Carisma Therapeutics股价,Carisma Therapeutics股市,Carisma Therapeutics股票价格,Carisma Therapeutics股票交易,Carisma Therapeutics股票购买,Carisma Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Carisma Therapeutics(CARM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Carisma Therapeutics(CARM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}